GlassScriptPhysician profile
John D Filippone
NPI 1720095060
$5,321.22
in general payments reported to CMS, 2019-2025
34 companies · $1,514 in 2025
The $1,514 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,084 · 2020: $309 · 2021: $221 · 2022: $503 · 2023: $677 · 2024: $1,014 · 2025: $1,514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,125 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,124.65 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $921.01 | 2019-2025 | |
| Pfizer INC. | $608.59 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $395.18 | 2020-2025 | Uptravi, Opsumit |
| Boston Scientific Corporation | $365.09 | 2019-2025 | Watchman Flx, Watchman Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $364.65 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $253.47 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $248.81 | 2019-2025 | Camzyos |
| Merck Sharp & Dohme LLC | $213.16 | 2022-2025 | Winrevair, Verquvo |
| Amgen INC. | $205.14 | 2019-2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $191.42 | 2019-2025 | Wainua |
| Abbott Laboratories | $163.28 | 2019-2025 | Cardiomems |
| Scpharmaceuticals INC. | $162.38 | 2024-2025 | |
| Abiomed | $126.81 | 2024-2025 | Impella |
| Medtronic, INC. | $103.17 | 2023-2025 | Azure Xt Dr Mri Surescan, Micra |
| Heartflow, INC. | $101.24 | 2024-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $100.29 | 2019-2024 | Lifevest |
| United Therapeutics Corporation | $94.72 | 2022 | |
| Alnylam Pharmaceuticals INC. | $92.53 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $88.01 | 2019-2020 | |
| Cvrx, INC. | $80.17 | 2022 | |
| Bridgebio Pharma, INC. | $80.11 | 2025 | Attruby |
| Edwards Lifesciences Corporation | $54.35 | 2025 | Sapien 3 Ultra Resilia |
| Regeneron Healthcare Solutions, INC. | $50.31 | 2019 | |
| Kestra Medical Technology Services, INC. | $49.58 | 2025 | Assure Wcd |
| Gilead Sciences, INC. | $38.91 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $27.95 | 2024 | Arcalyst |
| Agepha Pharma Fz LLC | $25.35 | 2025 | Lodoco |
| Sandoz INC. | $24.24 | 2023 | Treprostinil |
| Ionis Pharmaceuticals, INC. | $20.26 | 2025 | Tryngolza |
| Lexicon Pharmaceuticals, INC. | $16.47 | 2024 | |
| Novo Nordisk INC | $15.59 | 2025 | Wegovy |
| Sanofi-Aventis U.S. LLC | $14.17 | 2021 | |
| Sensible Medical Innovations INC | $13.99 | 2021 | |
| Medtronic Vascular, INC. | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Filippone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.